Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Santini D, et al. Among authors: marchetti p. Oncotarget. 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302. Oncotarget. 2016. PMID: 27027342 Free PMC article.
Premetastatic niche: ready for new therapeutic interventions?
Zoccoli A, Iuliani M, Pantano F, Imperatori M, Intagliata S, Vincenzi B, Marchetti P, Papapietro N, Denaro V, Tonini G, Santini D. Zoccoli A, et al. Among authors: marchetti p. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S119-29. doi: 10.1517/14728222.2012.656092. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443277 Review.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Bracarda S, et al. Among authors: marchetti p. Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3. Future Oncol. 2014. PMID: 24295376 Clinical Trial.
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Ascierto PA, et al. Among authors: marchetti p. Cancer Invest. 2014 May;32(4):144-9. doi: 10.3109/07357907.2014.885984. Epub 2014 Jan 31. Cancer Invest. 2014. PMID: 24484235
Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.
Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P. Gamucci T, et al. Among authors: marchetti p. J Cancer. 2014 Mar 20;5(5):320-7. doi: 10.7150/jca.8748. eCollection 2014. J Cancer. 2014. PMID: 24723974 Free PMC article.
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Santini D, et al. Among authors: marchetti p. PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014. PLoS One. 2014. PMID: 25170882 Free PMC article.
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. Vici P, et al. Among authors: marchetti p. Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. Oncotarget. 2016. PMID: 26910921 Free PMC article.
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Moscetti L, Vici P, Gamucci T, Natoli C, Cortesi E, Marchetti P, Santini D, Giuliani R, Sperduti I, Mauri M, Pizzuti L, Mancini ML, Fabbri MA, Magri V, Iezzi L, Sini V, D'Onofrio L, Mentuccia L, Vaccaro A, Ramponi S, Roma CL, Ruggeri EM. Moscetti L, et al. Among authors: marchetti p. Breast. 2016 Oct;29:96-101. doi: 10.1016/j.breast.2016.07.005. Epub 2016 Jul 29. Breast. 2016. PMID: 27476084
Brain Metastases: Surgical Treatment and Overall Survival.
D'Andrea G, Palombi L, Minniti G, Pesce A, Marchetti P. D'Andrea G, et al. Among authors: marchetti p. World Neurosurg. 2017 Jan;97:169-177. doi: 10.1016/j.wneu.2016.09.054. Epub 2016 Sep 22. World Neurosurg. 2017. PMID: 27667577
1,457 results